Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | GSR | P00390 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13815484 | 1.00 | CHRNB4 (0.40) | CHRNB4CHRNA3CYP3A4TSHRCYP2C19 | |
| SCHEMBL18544377 | 0.82 | CHRNB4 (0.43) | CHRNB4CHRNA3SLC18A3CA2GSR | |
| SCHEMBL23797352 | 0.78 | CHRNB4 (0.59) | CHRNB4CHRNA3AKR1C3AKR1C1 | |
| SCHEMBL30166929 | 0.78 | CHRNB4 (0.59) | CHRNB4CHRNA3AKR1C3AKR1C1 | |
| SCHEMBL221689 | 0.78 | CHRNB4 (0.59) | CHRNB4CHRNA3AKR1C3AKR1C1 | |
| SCHEMBL5070767 | 0.77 | KDM1A (0.48) | CYP3A4CYP2C19 | |
| SCHEMBL25796871 | 0.74 | CA2 (0.38) | CA2GSR | |
| SCHEMBL27053505 | 0.74 | CA2 (0.38) | CA2GSR | |
| SCHEMBL12405329 | 0.74 | KDM1A (0.41) | CHRNB4CHRNA3CA2GSR | |
| SCHEMBL31389967 | 0.73 | CHRNB4 (0.43) | CHRNB4CHRNA3AKR1C3AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350021-B1 | BRIDGED TETRAHYDRONAPHTHALENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-03-20 | — | — | EP | disclosed |
| US-8314253-B2 | Bridged tetrahydronaphthalene derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-11-20 | — | — | US | disclosed |
| US-20110263648-A1 | BRIDGED TETRAHYDRONAPHTHALENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263648-A1 | BRIDGED TETRAHYDRONAPHTHALENE DERIVATIVES | CACNA1E, CACNA1B, CACNB1 | CHRNB4 215/4885CHRNA3 207/4885CYP3A4 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.